Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tigris Pharmaceuticals

Criteria

Inclusion Criteria:

• ER+ or TN Breast Cancer

• Progression on an aromatase inhibitor if ER+

• Prior treatment with taxane if TN

• 18 years or older

• Adequate organ function

• Measurable lesion

Exclusion Criteria:

• symptomatic pulmonary disease

• brain metastases

• pregnant females